The Phase 3 PATINA trial demonstrates that adding palbociclib to maintenance anti-HER2 and endocrine therapy significantly improves progression-free survival in HR+/HER2+ metastatic breast cancer patients, increasing the median duration from 29.1 to 44.3 months, despite higher rates of neutropenia.